This study published in the World Journal of Diabetes evaluates the effect on cardiovascular outcomes of sodium-glucose co-transporter-2 (SGLT2) inhibitors in a real world setting by analyzing electronic medical records.
Manfred Paul Stapff, CMO, TriNetX Inc., Cambridge, MA 02140, United States
World J Diabetes. Dec 15, 2018; 9(12): 252-257
Chronic Lymphocytic Leukemia (CLL), a type of slow-growing cancer of the blood and bone marrow, accounts for 25-30 percent of all leukemia in the Western...
Powered By TriNetX MIT and BIDMC's study published by The Lancet introduces PRISM, a model for early pancreatic cancer risk, using a database of over 156...
In December, a contingent of our real-world data experts attended the 2022 Annual Meeting of the American Society of Hematology. Led by Chief Scientific...